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CWithdrawal of antihypertensive medication:
a systematic reviewVeronika van der Wardta, Jennifer K. Harrisonb, Tomas Welshc, Simon Conroyd,
and John GladmanaAlthough antihypertensive medication is usually continued
indefinitely, observations during wash-out phases in
hypertension trials have shown that withdrawal of
antihypertensive medication might be well tolerated to do in
a considerable proportion of people. A systematic review
was completed to determine the proportion of people
remaining normotensive for 6 months or longer after
cessation of antihypertensive therapy and to investigate the
safety of withdrawal. The mean proportion adjusted for
sample size of people remaining below each study’s
threshold for hypertension treatment was 0.38 at 6 months
[95% confidence interval (CI) 0.37–0.49; 912 participants],
0.40 at 1 year (95% CI 0.40–0.40; 2640 participants) and
0.26 at 2 years or longer (95% CI 0.26–0.27; 1262
participants). Monotherapy, lower blood pressure before
withdrawal and body weight were reported as predictors for
successful withdrawal. Adverse events were more common
in those who withdrew but were minor and included
headache, joint pain, palpitations, oedema and a general
feeling of being unwell. Prescribers should consider offering
patients with well controlled hypertension a trial of
withdrawal of antihypertensive treatment with subsequent
regular blood pressure monitoring.
Keywords: antihypertensive agents, antihypertensive
medication, cessation, hypertension, withdrawal
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ntihypertensive medication is usually continued
indefinitely, unless there are adverse effects that
alter the original judgement that the potential
benefits outweigh the potential harms. However, antihy-
pertensive medication is withdrawn for other reasons, such
as in preparation for trials of novel antihypertensive drugs.
When this is done, it has been observed that some patients
remain below the blood pressure (BP) threshold for restart-
ing antihypertensive treatment (AHT). If this were to be
sustained and well tolerated, attempted withdrawal of
antihypertensive medication could be part of the routine
management of hypertension – it would reduce the costs
and risks of the use of antihypertensive drugs – presumablyJournal of Hypertension
opyright © 2017 Wolters Kluwer Health, Inc. Unauwithout losing the benefits in those who truly need them.
Such attempted withdrawal might be particularly welcome
for patients wishing to reduce their medication load, those
deemed to be at high risk of problems from polypharmacy
or patient groups in which there is uncertainty about the
value of antihypertensive therapy – such as people with
dementia.
For the planned withdrawal of antihypertensive therapy
to be a worthwhile part of management, it would be
necessary not only for a reasonable proportion of patients
to be able to do so without needing to restart them, but they
would need to remain below the threshold for restarting
them for a considerable amount of time, and the process of
the planned withdrawal of antihypertensive therapy would
need to be safe. Planned withdrawal of antihypertensive
therapy could be more efficiently targeted if there were
reliable predictors of those who could and could not with-
draw successfully and sustainably.
We undertook a systematic review of the literature
describing studies in which antihypertensive therapy had
been withdrawn to determine the proportion of people
remaining within the threshold for restarting treatment for
at least 6 months, predictors for successful and sustained
withdrawal and the safety of doing so.
METHOD
The systematic review was based on a predefined protocol
(Prospero number CRD42016037130).
Eligibility criteria
Inclusion criteria: original research articles and abstracts
investigating withdrawal of antihypertensive medication inwww.jhypertension.com 1
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van der Wardt et al.human adults; studies including people diagnosed with
essential hypertension.
Exclusion criteria: animal studies, glaucoma and ocular
hypertension studies, studies limited to hypertension in
pregnancy, pulmonary hypertension studies, acute inter-
current illness, guanfacine studies (unless they include
other antihypertensive medications analysed separately),
systematic reviews, editorials, comments (unless on articles
included in the review).
Information sources
A meta-search was completed in Ovid using EMBASE
(1974–30 April 2015), Medline (1946–4th week April
2015), Medline in Process and other nonindexed citations
(30 April 2015), International Pharmaceutical Abstracts
(1970–April 2015) and PsychINFO (1806–4th week April
2015).
Search terms
Antihypertensive (exploded) AND Withdrawal OR cessa-
tion OR discontinuation OR stop
Filters were used where available to limit the search to
studies of humans aged at least 19 years written in English.
Data selection
After deduplication, V.v.d.W. screened titles and abstracts
based to identify eligible articles. Full texts for all eligible
articles were obtained and assessed by two independent
reviewers (V.v.d.W./T.W. or V.v.d.W./J.K.H.). When there
was no consensus between reviewers, disagreement was
resolved by discussion within the team.
Data extraction
The following data were extracted: author; year of publi-
cation; country; study design, sample characteristics,
eligibility criteria, primary outcomes, antihypertensive
medication before withdrawal, proportions remaining
below the authors’ thresholds for recommencement of
antihypertensive therapy at the time points reported in
each study (i.e. successful withdrawal), factors predicting
successful AHT withdrawal, adverse events or changes
potentially leading to adverse events.
Risk of bias assessment
Depending on study design, the appropriate Critical
Appraisal Skills Programme tool [1] was used to assess study
quality. Quality assessment findings are summarized in the
results section and reported for the individual studies in the
tables in Supplementary content 1 and 2, http://links.lww.
com/HJH/A776.
Analyses
Our outcomes of interest were as follows:2
Co1.pyThe proportion of people remaining below the
study’s threshold for hypertension treatment (i.e.
successful withdrawal).2. The effects associated with withdrawal.The proportion [and confidence intervals (CIs)] of
people successfully withdrawn from AHT was identifiedwww.jhypertension.com
right © 2017 Wolters Kluwer Health, Inc. Unauor calculated on the basis of percentages for each study
and summarized using means adjusted for sample size for
6 months (24–26 weeks), 1 year (52–60 weeks) and any
longer follow-up periods (between 72 weeks and 6 years).
If a study reported more than one result using different
analyses, the lower proportion was used. If a study reported
more than one result within a given analysis interval (e.g.
for 2 and 3 years), the result for the longer follow-up period
was used. Pearson’s correlation coefficient between the
year of publication and the proportion of people success-
fully withdrawn was calculated to investigate if there was a
relationship between the historical context of the study (i.e.
the hypertension guidelines at the time of the study) and the
success rate of withdrawal.
Factors predicting successful withdrawal and adverse
events were summarized in a narrative analysis; a quanti-
tative meta-analysis was not possible due to the hetero-
geneity of parameters reported. Studies investigating
adverse events or changes potentially leading to adverse
events are tabulated in Supplementary digital content 1,
http://links.lww.com/HJH/A776. A detailed analysis of
changes potentially leading to adverse events is shown
in Supplementary digital content 2, http://links.lww.com/
HJH/A776. Risk and changes potentially leading to adverse
events were structured by type of antihypertensive medi-
cation (if applicable).
RESULTS
In total, 66 articles were included in the review (Fig. 1) with
28 studies reporting proportions of people within the
threshold for treatment specified in the study for 6 months
or longer after withdrawal of antihypertensive therapy (a
description of the individual studies can be found in
Supplementary digital content 1, http://links.lww.com/
HJH/A776) and 49 studies reporting adverse events or
changes potentially leading to adverse events related to
withdrawal of antihypertensive medication (Supple-
mentary digital content 2, http://links.lww.com/HJH/
A776). Three studies [2–4] were not included in the analysis
of the proportion of people within the threshold for treat-
ment specified in the study. One reported a different
analysis of an already included study [5], which resulted
in a higher proportion of people within the threshold for
treatment specified in the study [2], and two did not provide
proportions but periods until hypertension returned [3,4].
For completeness of reporting, these studies were included
in Supplementary digital content 2, http://links.lww.com/
HJH/A776.
There was a significant negative relationship between
the year of publication and the rate of successful with-
drawal at 1 year (r¼0.52; P< 0.01; n¼ 26) with more
recent studies showing lower proportions of successful
withdrawal. There were no significant correlations between
year of publication and rate of successful withdrawal at
6 months or 2 years (for 6 months: r¼0.44, P¼ 0.20,
n¼ 10; for 2 years: r¼0.05, P¼ 0.86, n¼ 17).
Quality assessment
Most studies were relatively small, with sample sizes of n
less than 80. In the studies reporting the proportion ofVolume 35  Number 1  Month 2017
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Records idenﬁed (duplicates 
automacally removed in 
Endnote) and screened (tles and 
abstracts) n = 1437
Full-text arcles assessed for 
eligibility n = 292
Records excluded n = 11147
Not able to obtain n = 1
Studies included in analyses n = 66
Full-text arcles excluded 
total n = 226
No data on withdrawal 
n = 198
Comment/editorial/review 
n = 8
Withdrawal period too short 
n = 9
Not all AHT disconnued 
n = 10
Basic science n = 1
Studies reporng proporon of 
people remaining normotensive 
for six months or longer aer 
withdrawal of AHT n = 28
Studies reporng adverse events 
or changes potenally leading to 
adverse events related to 
withdrawal of AHT n = 49
FIGURE 1 PRISMA flow diagram.
Withdrawal of antihypertensive patients
Cpeople within the threshold for treatment specified in the
study, 15 out of 29 studies included sample sizes lower than
n¼ 80. In the studies reporting adverse events or changes
potentially leading to adverse events due to withdrawal of
antihypertensive medication, 37 out of 49 studies included
sample sizes lower than n¼ 80. Follow-up periods after
withdrawal to assess adverse events were largely short term
(29/49 studies reported adverse events for a follow-up of 1
month or shorter). The majority of studies were cohort
studies, only a fewwere designed as randomized controlled
trials (RCTs; 6/29 studies reporting the proportion of people
within the threshold for treatment specified in the study
were RCTs and 6/49 studies reporting adverse events or
changes potentially leading to adverse events were RCTs).
Proportion remaining normotensive after AHT
withdrawal
The analysis of studies reporting proportions of people
remaining normotensive for 6 months or longer included 21
cohort studies and seven RCTs (Supplementary digital
content 1, http://links.lww.com/HJH/A776). Thresholds
for treatment differed across studies with thresholds forJournal of Hypertension
opyright © 2017 Wolters Kluwer Health, Inc. UnauSBPs ranging from 135 to 200mmHg and threshold for
DBPs ranging from 85 to 129mmHg. Three studies did
not predefine a threshold but used a threshold depending
on physician advice or patient decision [6–8]. The mean
age reported in the studies ranged from 41 to 76 years. Out
of the 28 studies, 17 did not specify the type of AHT
withdrawn [3,6–22]. The remaining studies withdrew
angiotensin-converting enzyme inhibitors [23], angiotensin
II receptor antagonists [24], clonidine [23], beta blockers
[4,23,25–27], calcium channel blockers [23,24,28], diuretics
[2,4,5,21,25–27,29], reserpine [21] or vasodilators [4,21].
The follow-up interval ranged from 10 weeks to 6 years.
Only three studies provided details regarding the
withdrawal procedure [3,6,10] when multiple AHTs were
withdrawn.
The mean proportion of people successfully withdrawn
from AHT (adjusted for sample size) was 0.38 at 6 months
(95% CI 0.37–0.49; 912 participants) [6,8,17,19,21,22,24,
25,29], 0.40 at 1 year (95% CI 0.40–0.40; 2640 participants)
[5–7,9–12,14–18,22,24–28] and 0.26 at 2 years or longer
(95% CI 0.26–0.27; 1262 participants) [6,7,10,13,20–23,
25–29]. Figures 2–4 show the proportions and 95% CIswww.jhypertension.com 3
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0 0.2 0.4 0.6 0.8 1
0 (95% CI 0-0.03) Sasamura et al.,
2013** (one-sided)
0.02 (95% CI 0-0.06) Sasamura et
al., 2013*
0.59 (95% CI 0.50-0.68) Van Duijn
et al., 2011
0.35 (95% CI 0.15-0.59) Sieg-
Dobrescu et al., 2001†
0.52 (95% CI 0.45-0.59) Ayle et
al., 1999
0.28 (95% CI 0.14-0.45) Prasad et
al., 1997
0.62 (95% CI 0.46-0.76) Wahi et
al., 1993
0.55 (95% CI 0.46-0.63) Freis et
al., 1989
0.74 (95% CI 0.58-0.86) Danielson
et al., 1981
0.23 (95% CI 0.13-0.36) Veteran
Administrave Cooperave, 1975
Adjusted mean: 0.38 (95% CI 0.37-
0.39)
FIGURE 2 Proportion of people remaining normotensive at 6 months after antihypertensive treatment withdrawal. For Candesartan group; for Nifedipine group; yat 24
weeks.
van der Wardt et al.for each included study and themean proportions (adjusted
for sample size) and 95% CIs for 6 months, 1 and 2 years or
longer after AHT withdrawal. The majority of studies
included middle-aged and older people. Due to the variety
of measures of central tendency, a mean age could not
be calculated.
Factors associated with successful
antihypertensive treatment withdrawal
Factors associated with successful AHT withdrawal were
reported in 14 studies. The studies investigated a total of
18 parameters including, sex, age, ethnicity, height, body
weight, low-dose AHT or monotherapy, severity HT at
5–6 years previous to study, BP levels before withdrawal,
duration AHT, lower sodium levels, lower corpuscular
volume, higher serum albumin, baseline alcohol or
cigarette use, history of vascular disease, baseline of left
ventricular mass index, baseline ECG voltage and cardio-
vascular risk factors. Only five studies reported all variables
included in the statistical analysis, significant predictors and
appropriate statistics [8,12,16,23,29]. Based on the available
evidence, a meta-analysis was not possible. The studies
suggest that monotherapy of AHT and lower BP before
withdrawal predict successful withdrawal [7,8,10,15,16,23].
Although studies have also reported that body weight might
predict successful withdrawal, the evidence is conflicted;
although Fernandez et al. [5] and Nelson et al. [16] found4 www.jhypertension.com
Copyright © 2017 Wolters Kluwer Health, Inc. Unauthat higher body weight and greater waist–hip ratio pre-
dicted remaining normotensive after withdrawal, the results
of another cohort study suggested that lower BMI at base-
line [10] was a significant predictor of normotension after
AHT withdrawal.
What are the effects associated with withdrawal?
Studies investigating risks, that is adverse events and
changes that could lead to adverse events are tabulated
in Supplementary digital content 1, http://links.lww.com/
HJH/A776. The risks included general adverse events as
follows: changes in biochemistry, heart rate, pulse rate,
haemodynamics, kidney function, left ventricular
parameters, orthostatic hypotension and rebound hyper-
tension (results reported in Supplementary digital content
2, http://links.lww.com/HJH/A776).
The review identified one single-drug RCT, which
showed that there was no difference in adverse events at
1 month after withdrawal between those who stopped and
those who continued renin inhibitor or angiotensin con-
verting enzyme inhibitor treatment [30], although there
were significantly more adverse events reported in the
angiotensin-converting enzyme inhibitor groups compared
with the renin inhibitor group.
Some studies withdrawing centrally acting AHT or a
mixture of different hypertension treatments have shown
some minor side effects such as general malaise,Volume 35  Number 1  Month 2017
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0 0.2 0.4 0.6 0.8 1
0 (95% CI 0-0.03) Sasamura et al., 
2013TT (one-sided) 
0.09 (95% CI 0.05-0.15) Sasamura et 
al., 2013T
0.36 (95% CI 0.32-0.40) Nelson et
al., 2002®
0.30 (95% CI 0.23-0.37) Preston et
al., 2000
0.38 (95% CI 0.31-0.45) Ayle et al.,
1999
0.24 (95% CI 0.09-0.45) Prasad et
al., 1997
0.21 (95% CI 0.14-0.31) Myers et al.,
1996
0.59 (95% CI 0.39-0.76) Beltman et
al., 1996**
 0.83 (95% CI 0.64-0.94) Beltman et
al., 1996*
0.28 (95% CI 0.12-0.49) Jennings et
al., 1995
0.25 (95% CI 0.16-0.37) Fotherby &
Poer, 1994
0.60 (95% CI 0.55-0.65) Ekbom et
al., 1994
0.43(95% CI 0.28-0.59) Wahi et al.,
1993
0.36 (95% CI 0.27-0.45) Mitchell et
al., 1989
0.70 (95% CI 0.50-0.75) Alderman et
al., 1986
0.45 (95%CI 0.39-0.53) MRC 
working group, 1986††††
0.56 (95% CI 0.49-0.63) MRC 
working group, 1986†††
0.48 (95% CI 0.41-0.55)MRC 
working group, 1986††
0.57 (95% CI 0.50-0.63) MRC 
working group, 1986†
0.28 (95% CI 0.13-0.47) Langford et
al., 1984oooo
0.58 (95% CI 0.42-0.74) Langford et
al., 1984ooo
0.24 (95% CI 0.13-0.37) Langford et
al., 1984oo
0.52 (95% CI 0.34-0.68) Langford et
al., 1984o
0.23 (95% CI 0.17-0.30) Hansen et
al., 1983
0.66 (95%CI 0.48-0.81) Fernandez
et al., 1983***
0.55 (95% CI 0.38-0.71) Danielson
et al., 1981
Adjusted mean: 0.40 (95% CI 0.40-
0.40)
FIGURE 3 Proportion of people remaining normotensive at 1 year after antihypertensive treatment withdrawal. Using office blood pressure; using ambulatory blood
pressure monitoring; the study is reported in two articles with differing analyses: only results with lower percentage reported used (at 60 weeks); ymen, bendrofluazide
group; yymen propranolol group; yyywomen bendrofluazide group; yyyywomen propranolol group; the Nelson et al., [3] study was not included as this reported a different
analysis of the same study; TFor Candesartan group; TTfor Nifedipine group; ooverweight and mild HT; oooverweight and severe HT; ooonot overweight and mild HT; oooonot
overweight and severe HT.
Withdrawal of antihypertensive patients
Cpalpitations, joint pain, ankle oedema and headaches
[22,27,30,31].
A large cohort study with a long follow-up period
(5 years) demonstrated that those who had stopped anti-
hypertensive medication and were not advised by their
general practitioner to restart, had a lower risk ofJournal of Hypertension
opyright © 2017 Wolters Kluwer Health, Inc. Unaucardiovascular events and an equal mortality risk compared
with those remaining hypertensive. However, it is important
to note that patients who remained hypertensive included
people being treated for hypertension as well as those in the
placebo group of the STOP-Hypertension trial, which might
have led to a higher risk of cardiovascular events [7].www.jhypertension.com 5
thorized reproduction of this article is prohibited.
CE: Swati; JH-D-16-01127; Total nos of Pages: 8;
JH-D-16-01127
0 0.2 0.4 0.6 0.8 1
0.22 (95% CI 0.16-0.28) Ayle et
al., 1999xx
0.08 (95% CI 0.03-0.16) Schmieder
et al., 1997
0.48 (95% CI 0.29-0.67) Beltman et
al., 1996**
0.66 (95% CI 0.46-0.82) Beltman et
al., 1996*
0 (95% CI 0-0.14) Jennings et al.,
1995 (one-sided)
0.56 (95% CI 0.35-0.76) Van den
Bosch et al., 1994
0.20 (95% CI 0.11-0.32) Fotherby
& Poer, 1994
0.20 (95% CI 0.16-0.25) Ekbom et
al., 1994
0.33 (95% CI 0.20-0.50) Wahi et
al., 1993
0.43 (95% CI 0.18-0.71) Lernfelt et
al., 1990
0.23 (95% CI 0.17-0.31) Freis et al.,
1989
0.27 (95% CI 0.13-0.46) MRC 
working group, 1986††††
0.54 (95% CI 0.40-0.67) MRC 
working group, 1986†††
0.47 (95% CI 0.34-0.61)MRC 
working group, 1986††
0.44 (95% CI 0.30-0.59) MRC 
working group, 1986†
0.38 (95%CI 0.19-0.56) Danielson
et al., 1981
0.15 (95% CI 0.07-0.27) Veteran
Administrave Cooperave, 1975
Adjusted mean: 0.26 (95% CI 0.26-
0.27)
FIGURE 4 Proportion of people remaining normotensive at 2 years or longer after antihypertensive treatment withdrawal. xxBased on the results for 3-year follow-up
measurements; using office blood pressure based on diastolic BP only; using ambulatory blood pressure monitoring based on diastolic BP only; ymen, bendrofluazide
group; yymen propranolol group; yyywomen bendrofluazide group; yyyywomen propranolol group.
van der Wardt et al.DISCUSSION
The adjusted mean for the proportions of people remaining
normotensive after withdrawal of antihypertensive medi-
cation was 0.37 at 6 months and 0.26 at 2 years or longer.
This suggests that one in four people could be successfully
withdrawn from AHT for 2 years or longer. Monotherapy,
lower BP before withdrawal and body weight might predict
successful withdrawal. Adverse events were slightly more
common in those who withdrew than in those who con-
tinued and but were minor and comprised headache, joint
pain, palpitations, oedema and a general feeling of being
unwell.
Strength and limitations
Many of the studies identified were small, had a short
follow-up period, used different thresholds for hyperten-
sion and did not identify potential long-term risks such as
cardiovascular or cerebrovascular events. Nevertheless, we6 www.jhypertension.com
Copyright © 2017 Wolters Kluwer Health, Inc. Unauidentified 17 largely consistent studies including over 1000
patients in total studied for 2 years or more to show that
long-term withdrawal of antihypertensive therapy without
the return of hypertension was possible in 26%. Although
there will be concerns about the cessation of antihyperten-
sive therapy, the study with one of the longest follow-up
periods (5 years) indicated that those who had stopped
AHT and were not advised by their general practitioner to
restart AHT (withdrawal group), had a lower risk of cardio-
vascular events and an equal mortality risk compared with
those either remaining on treatment or included in a
placebo group [7]. We note that there was no consistent
correlation between the year of publication and the chance
of successful withdrawal of AHTs. An association was seen
for studies reporting at 1 year after AHT withdrawal,
but not for those reporting at 6 months or 2 years. If there
is an association, a possible explanation for it could be that
more modern studies used a combination of office
measurements, ambulatory BP monitoring and home BPVolume 35  Number 1  Month 2017
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Withdrawal of antihypertensive patients
Cmeasurements [32] thereby reducing the proportion of
patients who were over-diagnosed at outset. It is therefore
possible that lower rates of successful withdrawal of AHTs
will be seen in current practice than reported here. Our
study found a limited amount of evidence about the effects
of withdrawing some types of AHT such as renin inhibitors,
calcium antagonists, vasodilators or hydrochloride, and
so care must be taken in assuming that our findings apply
to all antihypertensive agents. Most studies in this review
included middle-aged and early older people and excluded
those who had cerebrovascular or cardiovascular events,
which means that our findings may not generalize to
patients at high vascular risk.
Our findings here are consistent with our earlier pre-
paratory review (a review of reviews), which indicated that
antihypertensive medication can be withdrawn in 22–50%
of people for 1 year or longer without hypertension return-
ing [31].
Just as the current review did not identify serious risks to
withdrawing AHT, similar results were found in the DANTE
trial, which included people who were 75 years or older
with mild cognitive deficits investigating the effects of AHT
withdrawal [33]. The results of this study showed that there
was no significant difference in adverse events between
withdrawal and control groups at 4 months after with-
drawal. The DANTE trial also confirmed the risk reduction
of orthostatic hypotension due to stopping AHT [32], which
was shown in one study included in this review.
CONCLUSION
The current review of the available evidence shows that
around one-quarter of mainly older patients on antihyper-
tensive therapy can withdraw such medication without
return of hypertension for 2 or more years. Doing so has
a small risk of minor side effects and if successful may be
associated with a lower cardiovascular risk in those with
lower BPs at the point of withdrawal. On this basis, it seems
reasonable for prescribers to consider using this evidence
to offer patients with well controlled hypertension a trial of
withdrawal of their antihypertensive medication. From a
practical perspective, the reporting of procedures regard-
ing the withdrawal of AHT was limited in the included
articles; however, details for planned AHT withdrawal
have been published elsewhere [34]. Because of the limita-
tions of the evidence, it should be noted that the safety of
this approach is not known for people at high cardiovas-
cular risk. Our findings indicate that attempting to with-
draw AHT will be more successful in those with lower BPs
and on single agents. However, given that three quarters of
patients attempting withdrawal will return to BPs that
would indicate the need to offer restarting antihyper-
tensive medication, stopping medication does not mean
an end to monitoring. Nevertheless, some patients may
wish to attempt, a trial of withdrawal – particularly those
for whom there is already doubt about the benefits of
antihypertensive therapy, such as in people with dementia
[35,36].
Further research would be wise to determine what
proportion of people agree to trials of withdrawal of their
antihypertensive therapy and the reasons for their choices.Journal of Hypertension
opyright © 2017 Wolters Kluwer Health, Inc. UnauStudies should examine the short and long-term benefits
and harms observed when doing so, particularly in groups
of patients in which deprescribing might be considered.
Research into programmes of deprescribing not focussed
solely on AHTs, for example in polypharmacy, should
take these findings into account when designing their
interventions.
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Reviewer 2
Withdrawal of antihypertensive therapy is a contentious
issue. This systematic review provides a good summary of
the evidence to date. Although the studies that have been
analysed varied in size and protocol design, a consistent
finding is that a significant proportion of people who were
well controlled on antihypertensive therapy did not revert
to hypertensive BP levels after their drugs were stopped. A
well conducted systematic review such as this can only be
hypothesis-generating and what would be needed is a large
trial with contemporary methods of blood pressure
measurement and more precise phenotyping of patients.Reviewer 3
Studies included in this systematic review on the effects of
withdrawal of antihypertensive therapy in hypertensive
patients were published between 1975 and 2013. During
this time, research criteria became more stringent, greater
emphasis was placed on randomized controlled trials, and
thresholds and targets of antihypertensive therapy have
become more evidence-based. Furthermore, ambulatory
and home BP became important in the management of
hypertension, so that it is highly likely that, without out-of-
office BP, the data analyzed in this studywere influenced by
white-coat hypertension. Therefore, the review is mainly of
historic interest and new studies are warranted, taking into
account contemporary guidelines for the management
of hypertension.Volume 35  Number 1  Month 2017
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